LSI Segment Divestment slide image

LSI Segment Divestment

Market Biologics Lonza Operations Continued strong demand for large- scale mammalian capacity Strong growth in trend towards outsourcing: Mammalian (pipeline dominated by small and mid-sized biotechs) Bioconjugates (demand for specialized facilities and knowledge) More than 500 drugs under investigation for COVID-19 in more than 1,360 clinical trials - CDMOs are playing a key role 1 Comparison versus 2019 at a constant exchange rate (CER) Overall contracting was strong: YoY increase in new customers and new program sign-ups High interest and new deals signed for Ibex® Dedicate, and customer base secured for mid-scale microbial capacity expansion High utilization of asset footprint, across clinical and commercial (small to large scale) Continued capacity expansion in 2021 across drug substance and product services Well-managed COVID-19 situation despite some limited supply and manufacturing risks Financial Performance¹ Strong double-digit (mid-teens) sales growth across 2020, driven by strong demand in all technologies Lower margin, driven by higher OPEX, related to growth projects 2021 expected to show third year of strong double-digit growth, mainly driven by strategic growth initiatives (P6, Ibex and Guangzhou) 24
View entire presentation